Roche announced positive results from two Phase 3 trials for its BTK inhibitor in multiple sclerosis, showing efficacy across relapsing and primary progressive forms. The outcomes mark a notable reversal for BTK drug development, a class that has faced prior setbacks and safety concerns. Roche described the trials as registrational and positioned the program to move toward regulatory submissions. The data will prompt competitive reassessment across MS pipelines and investor scrutiny of long‑term safety and comparative effectiveness versus existing disease‑modifying therapies.